Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Xenobiotica ; 54(3): 124-137, 2024 Mar.
Article in English | MEDLINE | ID: mdl-38358311

ABSTRACT

Nivasorexant was the first orexin-1 selective receptor antagonist entering clinical development. Despite encouraging preclinical evidence in animal models, a proof-of-concept trial in binge-eating patients recently failed to demonstrate its clinical utility in this population.Across species, nivasorexant clearance was driven by metabolism along seven distinct pathways, five of which were hydroxylation reactions in various locations of the molecule. The exact sites of metabolism were identified by means of mass spectrometry, the use of deuterated analogues, and finally confirmed by chemical references.CYP3A4 was the main cytochrome P450 enzyme involved in nivasorexant metabolism in vitro and accounting for about 90% of turnover in liver microsomes. Minor roles were taken by CYP2C9 and CYP2C19 but individually did not exceed 3-7%.In the rat, nivasorexant was mostly excreted via the bile after extensive metabolism, while urinary excretion was negligible. Only traces of the parent drug were detected in urine, bile, or faeces.


Subject(s)
Aryl Hydrocarbon Hydroxylases , Humans , Rats , Animals , Aryl Hydrocarbon Hydroxylases/metabolism , Orexins/metabolism , Orexins/pharmacology , Cytochrome P-450 Enzyme System/metabolism , Hydroxylation , Cytochrome P-450 CYP3A/metabolism , Microsomes, Liver/metabolism , Cytochrome P-450 CYP2C19/metabolism
2.
Xenobiotica ; 53(3): 173-183, 2023 Mar.
Article in English | MEDLINE | ID: mdl-36809238

ABSTRACT

Daridorexant is a dual orexin receptor antagonist developed for the treatment of insomnia disorder and has shown improvement in sleep outcomes and daytime functioning. The present work describes its biotransformation pathways in vitro and in vivo and provides a cross-species comparison between the animal species used in preclinical safety assessments and man.Daridorexant clearance is driven by metabolism along seven distinct pathways. Metabolic profiles were characterised by downstream products while primary metabolic products were of minor importance. The metabolic pattern differed between rodent species, with the rat reflecting the human pattern better than the mouse.In rodents, daridorexant is mostly excreted via the bile after extensive metabolism while urinary excretion was negligible in the rat. Only traces of the parent drug were detected in urine, bile, or faeces.Daridorexant has three major metabolites which are well covered in these preclinical safety species. All of them retain some residual affinity towards orexin receptors. However, none of these is considered to contribute to the pharmacological effect of daridorexant as their active concentrations in the human brain are too low.


Subject(s)
Orexin Receptor Antagonists , Sleep Initiation and Maintenance Disorders , Male , Rats , Humans , Mice , Animals , Imidazoles , Sleep Initiation and Maintenance Disorders/drug therapy , Pyrrolidines
SELECTION OF CITATIONS
SEARCH DETAIL
...